Outcome after treatment of distal radius fractures in the elderly using the IlluminOss® System

Abstract

Purpose Distal radius fractures are very common and account for approximately 17% of all fractures treated. Multiple treatment methods are available to treat these fractures, both operative and nonoperative. This study aimed at evaluating the functional and clinical outcomes after treatment of distal radius fractures with the IlluminOss ® System in adult patients. Methods A retrospective case series was performed in a single-level two-trauma center. All consecutive adult patients with a distal radius fracture, treated with the IlluminOss ® System between 01 August 2012 and 15 August 2015, were included in this study. Baseline patient characteristics and clinical data were retrospectively extracted from the medical records. Radial inclination, volar/dorsal tilt, ulnar variance, and radial length were measured on the latest available standard radiographs. In addition, patients were prospectively subjected to physical examination and were asked to complete the Disabilities of the Arm, Shoulder, and Hand, Patient-Rated Wrist Evaluation, and Short Form-36 questionnaires. Results Twenty-six patients with 31 distal radius fractures were included. The median age at time of trauma was 77 years and 96% were females. Five patients developed a total of seven complications. Due to persisting pain one reoperation was performed, removing a small prominent part of the implant. Both patient-reported outcome scores and radiographic results were good to excellent. Conclusions The IlluminOss ® System is a feasible option to treat distal radius fractures with seemingly good clinical and functional outcome. One out of seven complications required surgical intervention. These outcomes justify more detailed prospective research.

How I do it: Percutaneous stabilization of symptomatic sacral and periacetabular metastatic lesions with photodynamic nails

“…Our technique was the product of previous applications of PDN in the appendicular skeleton. [14][15][16][17] While our selected system was initially only FDA approved as a standalone implant for stabilization of the upper extremity (humerus, radius, and ulna), prior reports from Europe, where PDN is used more routinely in the F I G U R E 5 (A) A 72-year-old female with B-cell lymphoma presented with severe acetabular osteolytic metastatic disease with obvious subchondral collapse. (B) and (C) The acetabulum was stabilized with three photodynamic nails (PDN) (1 anterior column and 2 posterior columns), followed by a total hip replacement with screws passing through the PDN.…”

Photodynamic bone stabilization for traumatic and pathologic fractures: a systematic review of utilization, complications, and patient-reported outcomes

“…One Level III [ 9 ], Eight Level IV [ 1 , 2 , 5 – 7 , 12 – 14 ], and three Level V [ 8 , 15 , 16 ] studies reported complications following PBSS. A total of sixty complications were reported (Table 3 ).…”

“…Radiographic outcomes were reported by six Level IV studies and one Level V study (Table 4 ). Three studies[ 2 , 5 , 12 ] assessing fractures of the distal radius, metacarpals, humerus, and pelvis found complete fracture healing in all patients at 12-month follow up. Similarly, two studies [ 1 , 14 ] found 96% fracture healing among pelvic and humerus fractures, respectively.…”

Operative Fixation of a Humeral Shaft Periprosthetic Fracture After IlluminOss

“…The IlluminOss PBSS has shown promising clinical results for treatment of a plethora of upper and lower extremity impending, pathologic, and acute fractures 4,6,9,11,13,16,28 . The decision to use the IlluminOss PBSS in this patient was supported by early findings.…”

“…The clinical utility of PBSS is vast because authors have reported outcomes in both patients who required prophylactic fixation for impending fractures, as well as operative fixation of acute, traumatic, and/or pathologic extra-articular fractures 7,[11][12][13][14] . Despite early clinical success in Europe, the Illumi-nOss PBSS did not become approved by the US Food and Drug Administration until 2020 4,11 .…”